Statistical Trends in Pharmaceutical Research for Poor Countries

Introducing patent rights in developing country markets might stimulate greater R and D investment targeting their specific health needs – areas long neglected. This paper examines this argument using statistical data and survey evidence. We identify a set of diseases where 99 per cent of the burden is estimated to fall in lower income countries. Because science gaps and market potential will influence R and D priorities, this group is broke into a subset that already have low-cost and effect treatments, and those that to not.R and D, investment, health, statistical data, survey, diseases, burden, lower income countries, science, market potential, low cost, treatments, Pharmaceutical Research, poor countries, innovative, India, R&D, developing drugs, drugs